An Open-label, Single-arm, Multicenter Phase II/III Extension Study to Evaluate the Safety of Rituximab Re-treatment in Subjects With Moderate to Severe Systemic Lupus Erythematosus Previously Enrolled in Protocol U2971g
Phase of Trial: Phase II/III
Latest Information Update: 03 Aug 2017
At a glance
- Drugs Rituximab (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions
- Acronyms VOYAGER
- Sponsors Genentech
- 22 Dec 2009 Primary outcome amended as reported by ClinicalTrials.gov.
- 22 Dec 2009 Actual end date (July 2008) added as reported by ClinicalTrials.gov.
- 22 Dec 2009 Actual patient number (31) added as reported by ClinicalTrials.gov.